{
  "url": "https://openlegislation.uk/human-medicines-regulations-2012/regulation-279",
  "json_url": "https://openlegislation.uk/human-medicines-regulations-2012/regulation-279.json",
  "legislation": "uksi/2012/1916",
  "legislation_title": "The Human Medicines Regulations 2012",
  "legislation_url": "https://openlegislation.uk/human-medicines-regulations-2012",
  "path": "regulation/279",
  "kind": "regulation",
  "number": "279",
  "heading": "Products without a marketing authorisation etc",
  "text": "(1) A person may not publish an advertisement in Great Britain for a medicinal product unless one of the following is in force for the product—\n(a) a UKMA(GB) or UKMA(UK);\n(aa) an authorisation by the licensing authority on a temporary basis under regulation 174;\n(b) a COR(GB) or COR(UK); or\n(c) a THR(GB) or THR(UK).\n(2) A person may not publish an advertisement in Northern Ireland for a medicinal product unless one of the following is in force for the product—\n(a) a UKMA(NI) or UKMA(UK);\n(aa) an authorisation by the licensing authority on a temporary basis under regulation 174;\n(b) a COR(NI) or COR(UK);\n(c) a THR(NI) or THR(UK); or\n(d) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .\n(e) an Article 126a authorisation.\n(3) A person may not publish an advertisement in the whole United Kingdom for a medicinal product unless, in relation to that product—\n(a) one of the authorisations or registrations specified in paragraph (1) is in force in Great Britain; and\n(b) one of the authorisations or registrations specified in paragraph (2) is in force in Northern Ireland.",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "F",
      "label": "F1",
      "text": "Reg. 279 substituted (31.12.2020) by S.I. 2019/775, reg. 211 (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 167)"
    },
    {
      "type": "F",
      "label": "F2",
      "text": "Reg. 279(1)(aa) inserted (31.12.2020 immediately after S.I. 2019/775 comes into force) by The Human Medicines (Coronavirus) (Further Amendments) Regulations 2020 (S.I. 2020/1594), regs. 1(3), 11(a) and The Human Medicines (Coronavirus) (Further Amendments) Regulations 2020 (S.R. 2020/350, regs. 1(3), 11(a)"
    },
    {
      "type": "F",
      "label": "F3",
      "text": "Reg. 279(2)(aa) inserted (31.12.2020 immediately after S.I. 2019/775 comes into force) by The Human Medicines (Coronavirus) (Further Amendments) Regulations 2020 (S.I. 2020/1594), regs. 1(3), 11(b) and The Human Medicines (Coronavirus) (Further Amendments) Regulations 2020 (S.R. 2020/350), regs. 1(3), 11(b)"
    },
    {
      "type": "F",
      "label": "F4",
      "text": "Word in reg. 279(2)(c) inserted (1.1.2025) by The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024 (S.I. 2024/832), regs. 1(1), 121(a)"
    },
    {
      "type": "F",
      "label": "F5",
      "text": "Reg. 279(2)(d) omitted (1.1.2025) by virtue of The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024 (S.I. 2024/832), regs. 1(1), 121(b)"
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2012/1916/regulation/279",
    "retrieved_at": "2026-10-29T01:24:34.993203+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}